Yesterday, July 20, 2016, 17 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $23.69 to $362,467,980.00.

Highlighted Stocks Traded by Insiders:

AmTrust Financial Services (AFSI) - FREE Research Report

Saxon Michael J, who is EVP - U.S. Commercial Lines at AmTrust Financial Services, sold 9,000 shares at $24.59 on July 20, 2016. Following this transaction, the EVP - U.S. Commercial Lines owned 587,434 shares meaning that the stake was reduced by 1.51% with the 9,000-share transaction.

The shares most recently traded at $24.61, up $0.02, or 0.08% since the insider transaction. Historical insider transactions for AmTrust Financial Services go as follows:

  • 4-Week # shares bought: 100,000
  • 4-Week # shares sold: 9,000
  • 12-Week # shares bought: 100,000
  • 12-Week # shares sold: 28,000
  • 24-Week # shares bought: 100,000
  • 24-Week # shares sold: 49,000

The average volume for AmTrust Financial Services has been 828,500 shares per day over the past 30 days. AmTrust Financial Services has a market cap of $4.3 billion and is part of the financial sector and insurance industry. Shares are down 19.26% year-to-date as of the close of trading on Wednesday.

AmTrust Financial Services, Inc., through its subsidiaries, underwrites and provides property and casualty insurance in the United States and internationally. It operates in three segments: Small Commercial Business; Specialty Risk and Extended Warranty; and Specialty Program. The stock currently has a dividend yield of 2.43%. The company has a P/E ratio of 8.9. Currently, there are 5 analysts who rate AmTrust Financial Services a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AFSI - FREE

TheStreet Quant Ratings

rates AmTrust Financial Services as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full

AmTrust Financial Services Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Illumina (ILMN) - FREE Research Report

Epstein Robert S, who is Director at Illumina, sold 1,200 shares at $150.00 on July 20, 2016. Following this transaction, the Director owned 7,524 shares meaning that the stake was reduced by 13.76% with the 1,200-share transaction.

The shares most recently traded at $151.87, up $1.87, or 1.23% since the insider transaction. Historical insider transactions for Illumina go as follows:

  • 4-Week # shares sold: 716
  • 12-Week # shares sold: 8,939
  • 24-Week # shares sold: 58,931

The average volume for Illumina has been 1.2 million shares per day over the past 30 days. Illumina has a market cap of $21.9 billion and is part of the health care sector and drugs industry. Shares are down 20.5% year-to-date as of the close of trading on Wednesday.

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company's sequencing by synthesis technology provides researchers with various applications and the ability to sequence mammalian genomes. The company has a P/E ratio of 53.5. Currently, there are 4 analysts who rate Illumina a buy, 1 analyst rates it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ILMN - FREE

TheStreet Quant Ratings

rates Illumina as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Illumina Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Signet Jewelers (SIG) - FREE Research Report

McCluskey Helen, who is Director at Signet Jewelers, bought 1,000 shares at $89.91 on July 20, 2016. Following this transaction, the Director owned 6,197 shares meaning that the stake was boosted by 19.24% with the 1,000-share transaction.

Hobbs Sebastian, who is Managing Director, UK at Signet Jewelers, bought 500 shares at $91.72 on July 20, 2016. Following this transaction, the Managing Director, UK owned 8,684 shares meaning that the stake was boosted by 6.11% with the 500-share transaction.

The shares most recently traded at $88.77, down $2.95, or 3.32% since the insider transaction. Historical insider transactions for Signet Jewelers go as follows:

  • 4-Week # shares bought: 5
  • 4-Week # shares sold: 15,718
  • 12-Week # shares bought: 14,052
  • 12-Week # shares sold: 15,718
  • 24-Week # shares bought: 14,052
  • 24-Week # shares sold: 15,718

The average volume for Signet Jewelers has been 2.0 million shares per day over the past 30 days. Signet Jewelers has a market cap of $7.1 billion and is part of the services sector and specialty retail industry. Shares are down 27.6% year-to-date as of the close of trading on Wednesday.

Signet Jewelers Limited engages in the retail sale of diamond jewelry and watches in the United States, Canada, Puerto Rico, the United Kingdom, the Republic of Ireland, and the Channel Islands. The stock currently has a dividend yield of 1.15%. The company has a P/E ratio of 15.4. Currently, there are 11 analysts who rate Signet Jewelers a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SIG - FREE

TheStreet Quant Ratings

rates Signet Jewelers as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and attractive valuation levels. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Signet Jewelers Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.